A Phase II Open-Label Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer and Good Performance Status
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2018
Price : $35 *
At a glance
- Drugs CPI 613 (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 20 Aug 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 04 Jun 2018 Planned number of patients changed from 45 to 33.
- 14 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Aug 2018.